---
title: "An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer"
description: "This phase IV trial studies how well an investigational scan (18F-fluciclovine PET-CT) works for the measurement of therapeutic response in patients with p"
url: "https://www.clareohealth.com/clinical-trials/NCT04134208"
---

This phase IV trial studies how well an investigational scan (18F-fluciclovine PET-CT) works for the measurement of therapeutic response in patients with prostate cancer that has spread to other places in the body (metastatic). 18F-fluciclovine is a radioactive substance that is used in this study with PET-CT imaging scans that may help doctors learn about response to standard therapy in patients with prostate cancer.

## Key Facts

**ID:** NCT04134208
**Status:** TERMINATED
**Phase:** PHASE4
**Type:** INTERVENTIONAL
**Enrollment:** 2
**Sponsor:** M.D. Anderson Cancer Center

## About This Study

This clinical trial is testing an investigational scan called 18F-fluciclovine PET-CT to see how well it measures the response to treatment in men with metastatic prostate cancer. It focuses on patients whose cancer has spread and who have not yet received systemic therapy.

## Detailed Description

PRIMARY OBJECTIVE: I. Evaluate metabolic response by fluciclovine F18 (18F-fluciclovine) PET qualitatively and semi-quantitatively with standardized uptake values (SUV) following androgen deprivation therapy (ADT) plus abiraterone at 22-28 weeks (+/- 4 weeks), and correlate the findings with size changes as defined by conventional imaging and prostate-specific antigen (PSA) response. SECONDARY OBJECTIVES: I. To correlate pelvic 18F-fluciclovine PET imaging findings with pathologic findings at radical prostatectomy and pelvic lymph node dissection to determine 18F-fluciclovine PET imaging sensitivity and specificity for pelvic lymph node cancer involvement. II. To evaluate 18F-fluciclovine PET imaging response and its correlation with progression free survival (defined by Prostate Cancer Working Group 2 \[PCWG2\] criteria). III. To determine if sites of progressive disease develop at the initial/prior site (diagnostic site) of metastases or in newly developed sites at the time of metastatic progression. IV. To evaluate metabolic response by 18F-fluciclovine PET semi-quantitatively with target to blood pool ratio (TBR) following ADT plus abiraterone at 22-28 weeks (+/- 4 weeks), and correlate the findings with size changes as defined by conventional imaging and PSA response. OUTLINE: Within 4 weeks before starting standard systemic therapy (SST), patients receive fluciclovine F18 intravenously (IV) then undergo a PET-CT scan over 30 minutes. Within 22-28 weeks after starting SST, patients receive fluciclovine F18 IV and undergo a second PET-CT scan over 30 minutes.

## Conditions

- Metastatic Prostate Carcinoma
- Stage IVB Prostate Cancer AJCC v8

## Interventions

**PROCEDURE: Computed Tomography**
Undergo PET-CT scan

**DRUG: Fluciclovine F18**
Given IV

**PROCEDURE: Positron Emission Tomography**
Undergo PET-CT scan

## Eligibility

Inclusion Criteria: * Histologically or cytologically proven prostate carcinoma * Documented evidence of M1 disease by American Joint Committee on Cancer (AJCC) staging by bone sc…

## Who Can Participate

**Minimum age:** 18

**Sex:** MALE

**Accepts healthy volunteers:** No

## Study Locations

- M D Anderson Cancer Center, Houston, Texas, United States

## Contact Information

## Important Dates

**Study start:** September 19, 2019

**Completion date:** June 28, 2022

**Last updated:** January 16, 2025

## Collaborators

- National Cancer Institute (NCI)

## Consider Discussing with Your Care Team

### Worth Discussing If

- You have metastatic prostate cancer that has not been treated with systemic therapy yet.
- You are interested in understanding how well your treatment is working through advanced imaging.
- You want to explore new methods for monitoring your cancer's response to therapy.

### Questions to Ask

- What does the 18F-fluciclovine PET-CT scan involve?
- How will the results of this scan impact my treatment plan?
- Are there any risks or side effects associated with the scan?
- What happens if I qualify for this trial?
- How often will I need to come in for scans and treatments?
- What are the next steps if I decide to participate?

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04134208)
